A Retrospective Cohort Study: Influence of MTHFR C677T and A1298C Polymorphisms on the Survival of Pediatric Patients With Non-Hodgkin's Lymphoma

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04469543

Enrollment

374

Registered

2020-07-14

Start date

2014-01-20

Completion date

2020-05-20

Last updated

2020-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric Non-Hodgkin Lymphoma

Keywords

MTHFR C677T polymorphism；A1298C; Pediatric Non-Hodgkin Lymphoma；Survival.

Brief summary

The primary purpose of this retrospective study was to investigate the influence of methylenetetrahydrofolate reductase (MTHFR) C677T/A1298C polymorphism on the survival of pediatric patients with Non-Hodgkin lymphoma (NHL) treated with modified NHL-BFM95 protocol in south China.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

No minimum to 18 Years

Healthy volunteers

Inclusion criteria

1. aged ≤ 18 years; 2. newly diagnosed as the four main categories of NHL(Burkitt's lymphoma, lymphoblastic lymphoma, anaplastic large cell lymphoma, and diffuse large B-cell lymphoma) between 2014 and 2020; 3. treated according to the modified BFM95 protocol.

Exclusion criteria

1. aged \> 18 years; 2. not newly diagnosed as the four main categories of NHL between 2014 and 2020; 3. treated according to chemotherapeutic regimens except for the modified BFM95 protocol.

Design outcomes

Primary

Measure	Time frame	Description
Death	About six years	Overall survival time was calculated from the time of initial diagnosis to death
Events including progression, relapse, and secondary cancer	About six years	Event-free survival (EFS) time was calculated from the time of initial diagnosis to first event.

Countries

China

Outcome results